Ran Frenkel - Feb 7, 2022 Form 4 Insider Report for Karyopharm Therapeutics Inc. (KPTI)

Role
EVP, Chief Dev. Officer
Signature
/s/ Nancy Smith as Attorney-in-Fact for Ran Frenkel
Stock symbol
KPTI
Transactions as of
Feb 7, 2022
Transactions value $
-$19,635
Form type
4
Date filed
2/9/2022, 04:26 PM
Next filing
Feb 22, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KPTI Common Stock Sale -$19.6K -1.99K -1.87% $9.86* 105K Feb 7, 2022 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.
F2 The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 7, 2022 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees.
F3 Includes 861 shares and 1,323 shares acquired under the Karyopharm Therapeutics Inc. 2013 Employee Stock Purchase Plan on April 30, 2021 and October 31, 2021, respectively.